Antibacterial Xanthones from *Kielmeyera variabilis* Mart. (Clusiaceae)

Lucimar Pinheiro, Celso Vataru Nakamura*, Benedito Prado Dias Filho*, Antonio Gilberto Ferreira**, Maria Claudia Marx Young***, Diógenes Aparicio Garcia Cortez/+ 

Departamento de Farmácia e Farmacologia *Departamento de Análises Clínicas, Universidade Estadual de Maringá, Av. Colombo 5790, 87020-900 Maringá, PR, Brasil **Departamento de Química, Universidade Federal de São Carlos, São Carlos, SP, Brasil ***Instituto de Botânica de São Paulo, São Paulo, SP, Brasil +Dep. de Farmácia e Farmacologia, UEM, Maringá, PR, Brasil

The bioassay-guided fractionation of stems from *Kielmeyera variabilis*, traditionally used in Brazilian folk medicine, yielded assiguxanthone-B (1), kielcorin (4), 2,5-dihydroxybenzoic acid (3), and a mixture of xanthones containing assiguxanthone-B (1) and 1,3,5,6-tetrahydroxy-2-prenylxanthone (2) (1:1 w/w). The xanthone mixture inhibited *Staphylococcus aureus* and *Bacillus subtilis* at a concentration of 6.25 µg/ml. When tested alone, the minimal inhibitory concentration of assiguxanthone-B was 25 µg/ml against *B. subtilis*. Kielcorin and 2,5-dihydroxybenzoic acid were inactive against both strains. None of the fractions was active against *Escherichia coli* or *Pseudomonas aeruginosa*. Viable cells of *S. aureus* were reduced by a 1-3 log CFU/ml within 12 h after exposure of one to eight times the MIC of the xanthone mixture. It is not known whether the tetrahydroxy-2-prenylxanthone or other components of the xanthone mixture are responsible for the main antibacterial activity or whether additive or synergistic action is involved.

Key words: *Kielmeyera variabilis* - Clusiaceae - xanthones - antibacterial activity

*Kielmeyera variabilis* Mart. (Clusiaceae), a tree commonly known in Brazil as “malva-do-campo” (Syn. “paus-santo”), is traditionally used in Brazilian folk medicine to treat several tropical diseases including schistosomiasis, leishmaniasis, malaria, fungal and bacterial infections (Alves et al. 2000). A previous phytochemical investigation of the genus *Kielmeyera* reported activity of xanthones and biphenyl derivatives against *Cladosporium cucumerinum* and *Candida albicans* isolated from leaves and stems of *K. coriacea* (Cortez et al. 1998, 1999). No other literature reports were found on the chemical constituents of *K. variabilis*.

Inuma et al. (1996) have reported on the antibacterial activity of xanthones from the family Guttifereae against methicillin-resistant *Staphylococcus aureus* (MRSA). According to these authors, one active isolate, alphamangostin, a xanthone derivative had antibacterial activity. These authors reported that rubraxanthone, which is isolated from *Garcinia dioica* and has a structure similar to that of alpha-mangostin, had the greatest activity against staphylococcal strains.

The use and search for drugs and dietary supplements derived from plants have accelerated in recent years (Cowan 1999). Ethnopharmacologists, botanists, microbiologists, and natural-products chemists are combing the Earth for phytochemicals and “leads” which could be developed for treatment of infectious diseases. According to Cowan (1999), while 25 to 50% of current pharmaceuticals are derived from structures found in plants, very few are intended for use as antimicrobials.

Prompted by these reports, the present study was undertaken to investigate the in vitro antibacterial activity of the separated fractions of methanolic extracts from the stems of *K. variabilis*. We are reporting our results of the antibacterial activity of xanthones, isolated by bioassay-guided fractionation of the methanolic extract of the stems of *K. variabilis*. Time-kill studies were also performed to determine if xanthones had bactericidal activity.

**MATERIALS AND METHODS**

*Instruments* - ¹H and ¹³C nuclear magnetic resonance were performed on a Gemini 300 and a Bruker 400 NMR spectrometers (Varian, USA and Bruker, Germany respectively). Mass spectra were determined by VG Platform II and CG/EM - Shimadzu QP 2000 spectrometer (Micromass, USA and Shimadzu, Japan respectively).

*Plant collection* - Stems of *K. variabilis* were collected in Moji-Guaçu, São Paulo, Brazil, in April 1999 and a voucher (no. SP 346929) was deposited at the herbarium of the Instituto Botânico de São Paulo.

*Plant extract and fractionation* - The powdered stems (500 g) of *K. variabilis* were successively extracted at room temperature with hexane and methanol to give, after evaporation of the solvents and liophylization, 30 g of hexane extract and 34 g of methanol extract. The methanol...
and hexane extracts were screened for antimicrobial activity as described below. The methanol active extract was subjected to fractionation by vacuum chromatography on an Avicel® column and eluted with n-hexane, CH₂Cl₂, CH₂Cl₂-EtOAc (1:1), EtOAc, MeOH and (1:1), EtOAc, and MeOH to afford the fractions F1 (0.6 g), F2 (2.7 g), F3 (0.5 g), F4 (0.2 g), F5 (1 g), and F6 (0.4 g). The more active fractions, F3 and F4, were combined and submitted to gel chromatography on Sephadex LH-20 column chromatography using CHCl₃-MeOH (1:1) as eluent to give 40 fractions. Fractions, F3 and F4, were combined and submitted to gel chromatography on Sephadex LH-20 column chromatography using CHCl₃-MeOH (1:1) as eluent to give 40 fractions. Fractions 16 to 18 were combined and rechromatographed on Sephadex LH-20 and on silica gel 60 (230-400 mesh) (250 g) column chromatography eluted with hexane, hexane-EtOAc and EtOAc affording 2.2 g of a mixture of xanthones (compound 1 and 2). Fractions 19 to 21 were combined and rechromatographed on Sephadex LH-20 column chromatography eluted with MeOH, EtOAc and MeOH affording 4.6 mg of xanthone (compound 1) and 2.5 mg of organic acid (compound 3). The active fractions F5 and F6 were combined and chromatographed on Sephadex LH-20 column chromatography using MeOH, MeOH:H₂O (9:1) and MeOH:H₂O:EtOAc (45:5:1) as eluents to give 67 fractions. Fraction 10 (245 mg) was rechromatographed on Sephadex LH-20 yielding the active fraction 6 (53 mg), which was purified by preparative thin-layer chromatography (TLC) (silica gel GF₂₅₄, Hexane:CH₂Cl₂:MeOH, 5:4:1), affording 2.1 mg of xanthone (compound 1). Compounds 1, 2, 3, and 4 (Fig. 1) were identified as assiguxanthone-B (Chihiro et al. 1997), 1,3,5,6-tetrahydroxy-2-prenylxanthone (Goh et al. 1991), benzoic acid 2,5-dihydroxy (Bankova et al. 1987) and kielcorin (Pinto et al. 1987), respectively, by spectroscopic analysis and by comparison with literature data.

Microorganisms used and growth conditions - The following microorganisms were used for detecting antibacterial activity: Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 15442, Bacillus subtilis ATCC 6623 and S. aureus ATCC 25923. Cultures of these bacteria were grown in nutrient broth (Difco) at 37°C and maintained on nutrient agar slants at 4°C.

Antimicrobial susceptibility testing - The minimum inhibitory concentrations (MICs) of all compounds and reference antibiotics were determined by microdilution techniques in Mueller-Hinton broth (Merck S.A., São Paulo, Brazil) as described by the National Committee for Clinical Laboratory Standards (2000). Each inoculum was prepared in the same medium at a density adjusted to a 0.5 McFarland turbidity standard [10⁶ colony-forming units (CFU)/ml] and diluted 1:100 for the broth microdilution procedure. Microtiter trays were incubated at 37°C and the MICs were recorded after 24 h of incubation. Two susceptibility endpoints were recorded for each isolate. The endpoint MIC is the lowest concentration of a compound at which the microorganism tested does not demonstrate visible growth. Minimum bactericidal concentrations (MBCs) were defined as the lowest concentration yielding negative subcultures or only one colony.

Time-kill curve methodology - Prior to experimentation, the lower limit of bacterial quantification and the potential of compound carryover during the plating process were determined as previously described by the National Committee for Clinical Laboratory Standards (1999). According to these sampling procedures antibacterial carryover was not observed. Additionally, the lower limit of bacterial quantification was 100 CFU/ml. The effects of the xanthone mixture on the growth of S. aureus were determined by preparing a standardized suspension as described above. Dilutions yielded a starting inoculum of approximately 1x10⁶. The antibacterial activity of xanthone mixture was studied over a range of multiples of MIC encompassing 1 to 8X MIC. Tests were performed in triplicate with incubation at 37°C. At predetermined time points (0, 2, 4, 6, 8, 10, 12 h) a 100 µl sample was removed from each test solution, serially diluted in sterile water, and plated on Mueller-Hinton agar plates for colony count determination. Plates were incubated at 37°C for 24 h before colony count determination. Data from triplicate runs were averaged and plotted as log CFU/ml versus time (hours) for each time point.

RESULTS AND DISCUSSION

Screening tests of hexane and methanol extracts against S. aureus, E. coli, B. subtilis, and P. aeruginosa by using the microbroth MIC procedure are given in Table I. The results obtained with the methanol extract were more homogeneous, and both S. aureus and B. subtilis were considered susceptible with MICs of 3.9 µg/ml and 1.95 µg/ml, respectively. E. coli and P. aeruginosa with MIC >100 µg/ml were considered resistant.

As a result of this finding, the methanol active extract was fractionated on silica gel column chromatography in a bioassay-guided fractionation. Table II summarizes the MICs and Minimum Bactericidal Concentrations (MBCs) of isolated compounds and the xanthone mixture. The xan-

Fig. 1: compounds 1 (assiguxanthone-B), 2 (1,3,5,6-tetrahydroxy-2-prenylxanthone), 3 (2,5-dihydroxybenzoic acid), 4 (kielcorin) from Kielmeyera variabilis and 5 (calozeyloxanthone) from Calophyllum moonii.
As described above, bioassay-guided fractionation of methanolic extracts of the dry stems from *K. variabilis* permitted the isolation of assiguxanthone-B (1) and 1,3,5,6-tetrahydroxy-2-prenylxanthone (4). But under the conditions employed other active constituents of the xanthone mixture were not separated. Isolated assiguxanthone-B showed only moderate antibacterial activity (MIC 25 µg/ml) against *B. subtilis* in contrast with the methanol extract with MIC of 1.95 µg/ml. Whether the main antibacterial activity is due to 1,3,5,6-tetrahydroxy-2-prenylxanthone or the other components or whether activity is due to additive or synergistic action has not yet been determined. As discussed by Briskin (1999), in contrast to the synthetic pharmaceuticals based upon single chemicals, many phytomedicines exert their beneficial effects through additive or synergistic actions of several compounds acting at single or multiple target sites associated with a physiological process.

Finally, the results showed that the plant could be explored for possible antimicrobial agents and support its use for the treatment of wounds, which are contaminated with bacterial organisms.

### TABLE I
Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of hexane and methanol extracts from the stems of *Kielmeyera variabilis*

<table>
<thead>
<tr>
<th>Organism</th>
<th>MIC (MBC) (µg/ml)</th>
<th>Hexane extract</th>
<th>Methanol extract</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>62.5 (125)</td>
<td>3.0 (&gt; 100)</td>
<td></td>
</tr>
<tr>
<td><em>Bacillus subtilis</em></td>
<td>31.2 (62.5)</td>
<td>1.95 (62.5)</td>
<td></td>
</tr>
<tr>
<td><em>Escherichia coli</em></td>
<td>&gt; 100</td>
<td>&gt; 100</td>
<td></td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em></td>
<td>&gt; 100</td>
<td>&gt; 100</td>
<td></td>
</tr>
</tbody>
</table>

### TABLE II
Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of assiguxanthone-B, 2,5-dihydroxybenzoic acid, Kielcorin and assiguxanthone-B and 1,3,5,6-tetrahydroxy-2-prenylxanthone mixture from *Kielmeyera variabilis*

<table>
<thead>
<tr>
<th>Organism</th>
<th>Assiguxanthone</th>
<th>2,5-dihydroxybenzoic acid</th>
<th>Kielcorin</th>
<th>Assiguxanthone-B and 1,3,5,6-tetrahydroxy-2-prenylxanthone mixture</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>100 (100)</td>
<td>100</td>
<td>&gt; 100</td>
<td>6.25 (100)</td>
</tr>
<tr>
<td><em>Bacillus subtilis</em></td>
<td>25 (&gt; 100)</td>
<td>&gt; 100</td>
<td>&gt; 100</td>
<td>6.25 (25)</td>
</tr>
<tr>
<td><em>Escherichia coli</em></td>
<td>&gt; 100</td>
<td>&gt; 100</td>
<td>&gt; 100</td>
<td>&gt; 100</td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em></td>
<td>&gt; 100</td>
<td>&gt; 100</td>
<td>&gt; 100</td>
<td>&gt; 100</td>
</tr>
</tbody>
</table>
ACKNOWLEDGMENTS
To Marinete Martinez for her technical assistance.

REFERENCES


